SAN DIEGO—Ma Songjiang, President and Director of Gyre Therapeutics, Inc. (NASDAQ:GYRE), has reported the sale of company stock totaling $44,851, according to a recent SEC filing. The transactions, executed on December 17 and 18, involved the sale of 4,000 shares at prices ranging from $10.94 to $12.11 per share. The stock has shown recent momentum with a 9.41% gain over the past week, though it remains down 58.35% year-to-date, according to InvestingPro data.
These sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which was adopted on September 13, 2024. Following these transactions, Ma Songjiang now holds 2,938,467 shares indirectly through a family member.
Gyre Therapeutics, a pharmaceutical company based in San Diego, continues to focus on developing innovative treatments within the life sciences sector. The company maintains a strong liquidity position with a current ratio of 3.72, though InvestingPro analysis suggests the stock is currently trading above its Fair Value. For deeper insights into GYRE's financial health and additional ProTips, investors can explore InvestingPro's comprehensive analysis tools.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.